SecBot SecBot
PRESS-RELEASE ·Filed Nov 13, 2026

PDSB

PDS Biotechnology Corporation
NEUTRAL
Impact 4/10
Horizonmonths Processed3d 18h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The PIPE closing and warrant exercise by Nant Capital provide near-term liquidity but increase share count. The $10M milestone tied to a Phase 3 protocol submission for PDS0301 is pending and could trigger additional funding. Monitor for the FDA protocol submission and any partnership updates for PDS0101.

DirectionNeutral
Confidencemedium
Horizonmonths

Drugs in focus

PDSB drug pipeline →

PDS0301

◆ Mixed Named in this press release
Impact
Phase
Phase 2
Time to market
PDS0301 is in Phase 2 clinical development for metastatic colorectal cancer. Assuming successful Phase 2 data and a clear regulatory path, a registrational Phase 3 trial would likely take several years, meaning potential approval is likely 4+ years away under optimistic assumptions.
Next catalyst
None dated

What to watchPDS0301 is now PDS Biotech's sole internally-funded asset after the company discontinued its Phase 3 PDS0101 program in August 2026. The next catalyst is Q3 2026 earnings on November 12, 2026, where management may provide updates on the PDS0301 Phase 2 development plan and cash runway. Beyond that, watch for the company to outline a registrational path for PDS0301 in mCRC with liver metastases, which could involve an End-of-Phase 2 FDA meeting. The stock trades near $1.03 with a mean analyst target of $4.50, implying significant upside if the Phase 2 data translates into a viable registration strategy.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$0.8726
T+0 close · Nov 13, 2026 · via day close
Latest settled
+5.90%
T+1 · $0.9241
Vs SPY
+7.81%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $0.8726entry
  2. T+1 · 20h ago +5.90%α +7.81% · $0.9241
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PDS Biotech reported Q3 2026 net loss of $0.11 per share, narrower than the $0.19 loss a year ago, and below the consensus estimate of a $0.09 loss. The company completed the initial close of a $22.3M PIPE led by Nant Capital, which also exercised warrants and appointed two board members, providing near-term cash runway but diluting existing holders.

Key Financial Metrics

EPS
−$0.11
est −$0.09 · -22.2%
Revenue
$0.00
est $0.00
Rating
miss

Key Facts

  • Net loss per share of $0.11 for Q3 2026, vs $0.19 in Q3 2025 and consensus estimate of $0.09 loss
  • Cash and cash equivalents $15.2M as of September 30, 2026, down from $26.7M at year-end 2025
  • Initial closing of a PIPE financing of up to $22.3M led by Nant Capital
  • Nant Capital exercised 17.7M common warrants, converting into shares and pre-funded warrants, maintaining a 19.9% stake
  • Two Nant Capital designees appointed to the board
  • Operating expenses decreased to $5.9M from $8.1M year-over-year, driven by lower R&D costs
  • Net loss of $7.6M for the quarter, compared to $9.0M a year ago

Financial Impact

Net loss improved by $1.4M year-over-year; cash burn reduced; PIPE provides up to $22.3M in additional funding

net losscash positiondilution

Risk Factors

  • Cash runway limited to approximately 2 quarters at current burn rate without the full PIPE closing
  • Dilution from warrant exercises and PIPE issuance
  • Clinical-stage company with no approved products; reliance on successful trial outcomes and additional financing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3402547

Track record

28 reports on PDSB

Performance horizon

7 of 14 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 11 of 14 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Viewing Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
  2. Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
  3. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
  4. Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  5. Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  6. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
  7. Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
  8. Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
  9. Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
  10. Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
Showing 10 of 28

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026